Company news

Shield Therapeutics PLC news in 2024

Shield Therapeutics PLC's news releases, calls and decks from 2024, newest first.

View company

Result of General Meeting & Total Voting Rights

December 24, 2024

Results of RetailBook Offer

December 23, 2024

RetailBook Offer

December 6, 2024

Hardman & Co Investor Forum Research on Shiel...

November 21, 2024

Hardman & Co Video Event: Shield Therapeutics...

November 11, 2024

Q3 Trading Update

October 29, 2024

Results from Phase 3 paediatric study

September 25, 2024

Hardman & Co Research on Shield Therapeutics...

September 11, 2024

Interim results

September 4, 2024

ACCRUFeR® Approved by Health Canada

August 27, 2024

Notice of interim results

August 14, 2024

Unaudited Q2 2024 Trading Update

July 24, 2024

$5.7m Milestone Monetization Agreement with AOP

July 3, 2024

Results of 2024 Annual General Meeting

June 20, 2024

New Drug Application for Accrufer® in South Korea

May 28, 2024

Hardman & Co: Shield Therapeutics (STX): Cash...

May 23, 2024

Audited results for the year ended 31 Dec 2023

May 10, 2024

Business Update for Q1 2024

April 30, 2024

Notice of Results

April 16, 2024

Unaudited Full Year Trading Update

February 21, 2024

Appointment of new Chief Financial Officer

January 9, 2024

Calls in 2024

Decks in 2024